summari expect report sale could exceed
consensu forecast least meet/potenti beat ep
estim revenu ep compar
consensu respect top-lin estim
impli organ growth slightli
analysi recent im trend suggest potenti upsid jnj
us consum segment consist
expect cautious optimist head jnj
report base ims/nielsen data analysi manag
recent optimist tone expect jnj guidanc
organ sale growth remain intact could see slight
improv ep guidanc rais ep
estim slightli ahead consensu
note also track perform key us
drug base im data
expect upsid us pharma estim sale
consensu organ growth assum growth
acceler consum vs slow somewhat
pharma medic devic estim organ pharma sale
growth vs analysi im data
suggest key us drug exceed expect
rais forecast still somewhat conserv vs im
trend reflect potenti upsid consum estim
organ growth vs medic devic
estim organ growth vs
expect sale guidanc remain intact estim
overal sale consensu organ
growth slightli high-end jnj guidanc
pharmaceut improv growth medic devic
consum expect improv growth driven new
launch accret recent acquisit like amo vogu
forecast assum gener zytiga start
meaning news expect jnj pharma pipelin
believ shape anoth busi year
jnj pharma busi term new launch clinic data
read approv front erleada came earlier expect
alreadi darzalex
cad/pad
coronary/peripher arteri diseas pend addit
expect file esketamin erdafitinib well line extens
xarelto erleada imbruvica help creat addit
growth driver host call dr mathai
mammen global head scienc develop janssen
discuss jnj strategi pipelin
line xarelto
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani prioriti stock list
compani data secur llc estim reuter
us pharma like outperform report result estim total sale
organ growth vs growth ahead consensu
ep estim line consensu forecast forecast includ fx tailwind
slightli lower compar jnj report januari model assum slight growth
deceler medic devic pharma small acceler consum vs pharma
estim organ sale growth vs consum estim organ
growth vs analysi im data suggest sever key us drug
could outperform expect review nielsen data point low-singl digit growth
consist model medic devic estim organ growth vs
fx tailwind littl chang analysi suggest fx tailwind slightli lower
time jnj report estim fx benefit bottom-lin
repres full year fx benefit guidanc
im sale suggest potenti out-performance us pharmaceut analysi im data
key drug suggest potenti upsid sever key us drug includ stelara xarelto figur
specif rais us sale forecast stelara xarelto
invokana partli off-set lower forecast darzalex
potenti modest upsid product simponi/aria uptravi believ
magnitud potenti upsid insuffici warrant rais number net-net
increas us pharma sale estim monthli product tracker detail start
price increas consist recent histori review wac wholesal acquisit cost
increas key us drug consist histori rais price across much
portfolio increas rang price increas rang
darzalex zytiga figur includ increas new psoriasi drug tremfya
compani report secur llc estim organ growth adjust fx acquisitions/divestitur extra sell day prior price adjust ppa pharma venezuela note amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate organ growth busi segmentsex-fx growthoct nov growthim estimate estpharma salesremicad im health medi-span clinic drug inform llc compani report secur llc estim price increas effect extrapol assum oct nov repres sale wac sale growth johnson johnson
us consum growth in-lin report organ consum sale growth
ww compar manag attribut softer
growth tougher yr/yr comp minor suppli disrupt follow hurrican maria analysi
aggreg nielsen data suggest jnj us consum growth
low-singl digit direct consist estim figur aggreg
nielsen data appear trend direct consist report sale organ growth
time figur c-d forecast ww consum sale organ growth vs
includ us sale vs
nielsen sale base aggreg data
nielsen sale base aggreg data
expect sale guidanc remain intact could see upward revis ep
guid organ sale growth report sale expect
outlook remain intact quarter belt continu expect modest yr/yr
growth acceler consum medic devic busi year guid
ep midpoint rang could see move modestli base solid
perform analysi recent currenc rate suggest fx tailwind may modestli
reduc although would expect absorb neg impact guidanc fx tailwind
recent announc diabet divestitur alreadi contempl guidanc expect atln
accret remain around year
host spotlight call april estim pharma busi
grow organ slight deceler adjust gross-to-net price
adjust medic devic consum busi expect grow low-singl digit
year pharma remain key driver overal organ sale growth guidanc
host call mathai mammen md phd global head scienc develop
janssen discuss jnj strategi pipelin highlight near- medium-term
among pipelin highlight darzalex front-lin multipl myeloma erleada prostat cancer
erdafitinib bladder cancer esketamin treatment-resist depress xarelto coronari arteri
disease/peripher arteri diseas summari key pipelin event figur
impact biosimilar remicad still appear limit im data show biosimilar remicad
continu ramp slowli sale increas januari juli
februari figur entri second biosimilar six month ago materi chang
trajectori biosimilar penetr time im sale show trail averag
remicad sale remain rel unchang past year howev quarterli
remicad im sale growth slow mid- high-singl digit pre-biosimilar flattish recent
quarter said growth deceler still appear benign estim
year forecast us remicad sale ex-export declin although forecast
seem conserv recent im sale trend suggest sale closer chang
forecast believ above-averag discounting/reb help remicad maintain
share thu reduc net report sale
februari celltrion announc receiv warn letter wl incheon facil
biosimilar inflectra manufactur wl follow issu fda septemb
although celltrion expect wl affect abil suppli inflectra partner believ
could slow celltrion manufactur process constrain suppli could posit see
note celltrion manufactur issu could help remicad date addit detail
note still on-going patent litig anti-competit lawsuit compani
although dont visibl potenti time resolut
darzalex overal share multipl myeloma mm increas despit dip line use fda
approv darzalex use revlimid velcad plu dexamethason relapsed/refractori r/r mm
patient receiv least one prior therapi novemb sinc drug share
line treatment jump septemb dip februari
accord brandimpact survey figur line darzalex share jump februari
well share rang much figur darzalex held overal market
share survey despit share line use expect darzalex penetr line
continu rise approv front-lin use start help drive uptak line
overal share gain present posit interim data alcyon trial line use
american societi hematolog file approv late data maia studi
line expect later lower darzalex sale estim
yr/yr growth base recent im sale trend
imbruvica front-lin cll use continu drive growth first-lin cll chronic lymphocyt
leukemia indic remain key driver imbruvica adopt six total approv
indic call reiter imbruvica market leader across line therapi
cll compani guid us imbruvica sale impli us revenu
line forecast base roll data growth
averag weekli averag figur partnership book
sale book ou sale split global profit estim us imbruvica
revenu impli end-us sale seem reason base im
sale trend estim ww imbruvica revenu impli end-us sale
invokana/invokamet rx volum market share continu fall invokana franchis
volum fell january/februari slightli wors averag declin figur
weekli im data show similar trend march
vs last week figur invokana/invokamet rx volum declin continu
sinc canvas/canvas-r outcom data ada american diabet associ meet june
recal data show invokana effect reduc cardiovascular risk also
led significantli higher rate amput fractur patient treatment
within class invokana/invokamet nrx share also continu fall reach februari
vs juli comparis competitor azn farxiga/xiguo xr increas
january/februari bi/lli jardianc franchis share maintain
averag share earli figur jardianc signific share gain month
doubl driven posit data label updat base
empa-reg outcom trial show drug lower cardiovascular risk increas
amputation/fractur risk growth overal categori slow
january/februari increas us invokana sale
base recent im sale trend although remain cautiou franchis given
deterior rx trend estim ww invokana/invokamet sale
latitud continu drive strong zytiga growth sinc present latitud data
american societi clinic oncolog june zytiga im rx sale growth
rebound remain robust earli recal latitud show zytiga significantli
improv surviv patient hormone-nav prostat cancer zytiga trx nrx volum grew
respect februari compar larg declin rx volum pre-latitud figur
zytiga im sale also grow februari sale vs flattish low-singl digit growth prior
latitud figur file latitud data fda septemb suggest
label expans earlier treatment stage like im sale trend suggest us
zytiga sale estim increas us
zytiga revenu growth also rais full year us zytiga revenu
estim assum gener competit start follow possibl
earli erleada approv help partli off-set zytiga headwind see latitud
continu drive zytiga growth anniversari data like gener competit late
weigh significantli busi year although earlier expect approv
erleada apalutamid help off-set headwind still estim jnj us prostat
cancer franchis sale fall yr/yr low- mid-singl digit ww
week erleada rx data earli discern meaning trend continu await
decis summari judgment sj case recal review transcript
oral argument consult suggest like prevail case see note
erleada came early-gener zytiga unlik date court side
sj motion would expect patent case proceed full trial possibl around mid-year
resolut time stay expir octob
xarelto rx growth stabl share continu declin februari eliqui maintain
lead among novel oral anticoagul noac share m/m follow xarelto
share pradaxa share past month xarelto lost
market share eliqui gain share figur februari xarelto trx
nrx volum rose respect mid-teen averag growth figur
contrast overal noac market nrx volum grew februari consist
growth trend noac account oral anticoagul nrx decemb
xarelto launch juli figur increas us xarelto sale
estim growth easi comp base recent im trend
continu believ xarelto growth possibl share could improv later
addit compass data label recal file compass data late
xarelto target patient popul help differenti drug profil
jnj long-act atyp franchis growth steadi im sale jnj long-act
inject atyp laia franchis sustenna trinza risperd consta grew februari in-lin
high-teen averag growth figur steadi growth larg reflect strong growth
sustenna trinza partli off-set mid-singl digit declin consta nearli year trinza sale
track larg in-lin sustenna sale time post launch figur trinza current
account franchis sale franchis growth accord im
us laia market maintain lead risperd consta invega sustenna/trinza hold
nrx share februari although lost share past year ostuka abilifi maintena
hold share aristada share figur estim ww sustenna/trinza
includ us sale growth believ reason base recent
robust stelara im sale growth continu stelara im sale grew january/februari in-lin
growth trend figur trx volum specialti show crohn remain key
growth driver monthli written gastroenterolog specialist stelara tripl
past year rheumatologist also support continu stelara growth
dermatologist stelara trx pace declin remain modest
expect given competit tremfya launch increas us stelara sale
estim yr/yr growth base recent im sale data forecast ww
stelara sale
tremfya launch still earli encourag base third-parti data tremfya
market month im sale annual base februari data tremfya
weekli volum lag behind stelara nv cosentyx lli taltz time post-
launch figur physician prescrib data suggest uptak solid accord
brandimpact tremfya alreadi rank share new written prescript behind nv
cosentyx furthermor combin tremfya stelara share brandimpact survey increas
pt januari jnj recent public commentari also suggest
drug may perform better trend suggest im due free sampl continu see
tremfya import growth driver jnj pharma franchis assum stelara growth
slow due cannib tremfya competit cosentyx taltz accord
im cosentyx sale annual taltz sale annual track ahead
stelara time post-launch figur cosentyx/taltz price stelara
simponi/aria robust im sale growth continu earli februari simponi im sale
rose vs aria im sale grew vs togeth drive
franchis growth vs februari eight consecut month double-digit
franchis im sale growth sinc june figur believ franchis continu growth
momentum earli bode well rest year estim ww
simponi/aria sale includ us sale growth may slightli
conserv base im sale trend enough us rais forecast
opsumit tracleer uptravi appear track least in-lin expect
close acquisit atln track im sale trend top three
atln drug opsumit tracleer uptravi figur togeth repres atln
us sale grew caveat track may limit util im sale
histor captur report opsumit/uptravi sale report tracleer sale
estim us opsumit sale pro forma pf growth extrapol
im sale growth direct consist trend report pf growth vs
im sale growth estim us tracleer sale pf declin slightli
benign extrapol im sale declin also direct consist trend
report pf declin vs im sale declin estim us uptravi sale
pf growth slightli extrapol im sale growth report pf sale growth
far outpac im sale growth suggest could see upsid uptravi
forecast howev chang model given unexpect weak sale trend result
time foundat fund limit histor im vs report sale trend
reportedim us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum march im sale repres johnson johnson
compris mostli pfe/celltrion inflectra
figur darzalex share dip line multipl myeloma market
figur darzalex share climb line multipl myeloma market
rxtrxnrxfeb cll approvedmar front-lin cll approvedjul r/r cll label expans includ mutat jan waldenstrm macroglobulinemia approvedaug graft-vs-host-diseas cgvhd growthmonthli trxtrx volumetrx rx y/i add black box warn leg foot amput present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney injuri johnson johnson
figur invokana franchis lose share market
figur zytiga monthli volum growth trend improv
new oral anticoagul includ pradaxa xarelto eliqui savaysa
growth trxtrx growthtrx nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedeliqui dvt prevent approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment approv johnson johnson
sale month launchinvega sustennarisperd constainvega growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd consta medic technolog
figur taltz cosentyx launch outpac stelara tremfya
figur atln opsumit im sale growth continu
figur atln tracleer im sale continu declin
figur atln uptravi im sale remain solid launch trajectori
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
potenti approv us/eudarzalex alcyon front-lin multipl myeloma nontranspl us/eu us apalutamid prostat cancer us febsymtuza darunavir str d/c/f/taf hiv us metastat prostat cancer us edur dolutegravir fdc viiv hiv mainten treatment eu invokanacanvas/canvas-r-cv outcom us combo w/ rituximabtn wm us plan submiss us/euesketaminetreat resist depress trd us/eu xarelto line extensionschf us/eu imbruvica line extensionscl front-lin mainten us/eu diffus larg cell lymphoma us/eu combo w/ rituximab wm us/eu erdafitinibbladd cancer us/eu opsumitcteph chronic thromboembol pulmonari hypertens us/eu erleada zytigachemo nave prostat cancer eu erleadapre-metastat prostat cancer eu potenti clinic data present base studi primari complet feb genitourinari cancer symposium pre-metastat prostat may trd ulcer frontlin cll combo phoenix dlbcl frontlin inov combo w/ rituximab darzalexmaia w/ revlimid dex front-lin mm xarelto explor program command hf chf marin vte prevent medic ill pt symtuzahivtremfya self dose devic orion dlbl relaps frontlin cll iv fix durat hiv vaccineasc travers hiv darzalexphas griffin front-lin mm feb genitourinari cancer symposium bladder cancer phase medic technolog
price target nc
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect overal growth improv multipl tailwind recent acquisit start
contribut organ
johnson johnson world comprehens broadli base manufactur health care
product servic consum pharmaceut medic devic market medic devic
segment consist primarili product cardiovascular orthoped surgic diabet vision
compani report sale year-over-year constant currenc
